The United States Patent and Trademark Office has issued a patent for Lorus Therapeutics' LOR-253, which covers composition of matter and methods of treating cancer.
The patent was initially set to expire in May 2026 and latter was granted a patent term adjustment that extends the expiry date to February 2028, the company said.
The small molecule anticancer drug is in Phase I trial which will assess the safety profile and antitumor activity and will determine the recommended dose for subsequent Phase II trials.
Lorus president and CEO Aiping Young said: "Allowance of our US patent for LOR-253 is vital for the continued growth of Lorus, and is in line with our core IP strategy, which is to obtain exclusivity for LOR-253 in key markets."